{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:02:16Z","timestamp":1789437736760,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01239-y","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:19:06Z","timestamp":1782404346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures"],"prefix":"10.1186","volume":"24","author":[{"given":"Ilaria","family":"Maccora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Inguscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ant\u00f3n-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1239_CR1","doi-asserted-by":"publisher","unstructured":"Clarke SLN, Sen ES, Ramanan A V. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol. 2016;14(1). https:\/\/doi.org\/10.1186\/s12969-016-0088-2.","DOI":"10.1186\/s12969-016-0088-2"},{"key":"1239_CR2","doi-asserted-by":"publisher","unstructured":"Mastrangelo G, Foeldvari I, Anton J, Simonini G. Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus? Pediatr Rheumatol. 2019;17(1). https:\/\/doi.org\/10.1186\/s12969-019-0330-9.","DOI":"10.1186\/s12969-019-0330-9"},{"issue":"3","key":"1239_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","volume":"244","author":"PE Carvounis","year":"2006","unstructured":"Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefe\u2019s Arch Clin Exp Ophthalmo. 2006;244(3):281\u201390. https:\/\/doi.org\/10.1007\/s00417-005-0087-3.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmo"},{"key":"1239_CR4","doi-asserted-by":"publisher","unstructured":"Foeldvari I, Klotsche J, Simonini G, et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the multinational interdisciplinary Working group for uveitis in childhood (MIWGUC). Pediatr Rheumatol. 2019;17(1). https:\/\/doi.org\/10.1186\/s12969-019-0345-2.","DOI":"10.1186\/s12969-019-0345-2"},{"key":"1239_CR5","doi-asserted-by":"publisher","unstructured":"Denniston AK, Keane PA, Srivastava SK. Biomarkers and surrogate endpoints in uveitis: the impact of quantitative imaging. Invest Ophthalmol Vis Sci. 2017;58(6):BIO131\u201340. https:\/\/doi.org\/10.1167\/iovs.17-21788.","DOI":"10.1167\/iovs.17-21788"},{"key":"1239_CR6","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"1239_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.clim.2019.108327","volume":"211","author":"A Schnabel","year":"2020","unstructured":"Schnabel A, Unger E, Br\u00fcck N, et al. High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: a retrospective analysis. Clin Immunol. 2020;211:211. https:\/\/doi.org\/10.1016\/j.clim.2019.108327.","journal-title":"Clin Immunol"},{"key":"1239_CR8","doi-asserted-by":"publisher","unstructured":"Slamang W, Tinley C, Brice N, Scott C. Paediatric non-infectious uveitis in Cape Town, South Africa: a retrospective review of disease characteristics and outcomes on immunomodulating treatment. Pediatr Rheumatol. 2021;19(1). https:\/\/doi.org\/10.1186\/s12969-021-00537-x.","DOI":"10.1186\/s12969-021-00537-x"},{"key":"1239_CR9","doi-asserted-by":"publisher","unstructured":"Al-Julandani D, Bagri N, Tsang N, et al. Outcome of adalimumab monotherapy in paediatric non-infectious uveitis. Pediatr Rheumatol. 2023;21(1). https:\/\/doi.org\/10.1186\/s12969-023-00794-y.","DOI":"10.1186\/s12969-023-00794-y"},{"issue":"5","key":"1239_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41433-023-02795-3","volume":"38","author":"EO Kreps","year":"2024","unstructured":"Kreps EO, Epps SJ, Consejo A, Dick AD, Guly CM, Ramanan A V. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye (Basingstoke). 2024;38(5):871\u201376. https:\/\/doi.org\/10.1038\/s41433-023-02795-3.","journal-title":"Eye (Basingstoke)"},{"issue":"6","key":"1239_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/09273948.2022.2126374","volume":"32","author":"G Uludag","year":"2024","unstructured":"Uludag G, Karaca I, Akhavanrezayat A, et al. Efficacy and safety of Tocilizumab in the management of non-infectious uveitis failed with conventional Immunomodulatory and anti-TNF\u03b1 therapies. Ocul Immunol Inflamm. 2024;32(6):891\u201397. https:\/\/doi.org\/10.1080\/09273948.2022.2126374.","journal-title":"Ocul Immunol Inflamm"},{"key":"1239_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fped.2022.851453","volume":"10","author":"I Maccora","year":"2022","unstructured":"Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and Abatacept for the treatment of childhood chronic uveitis: a Monocentric comparison Experience. Front Pediatr. 2022;10:10. https:\/\/doi.org\/10.3389\/fped.2022.851453.","journal-title":"Front Pediatr"},{"key":"1239_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jtauto.2024.100247","volume":"9","author":"I Maccora","year":"2024","unstructured":"Maccora I, Soldovieri S, Oliverio T, et al. To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF. J Transl Autoimmun. 2024;9:9. https:\/\/doi.org\/10.1016\/j.jtauto.2024.100247.","journal-title":"J Transl Autoimmun"},{"issue":"4","key":"1239_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12098-021-03884-5","volume":"89","author":"P Kumar","year":"2022","unstructured":"Kumar P, Gupta A, Bansal R, et al. Chronic uveitis in children. Indian J Pediatr. 2022;89(4):358\u201363. https:\/\/doi.org\/10.1007\/s12098-021-03884-5.","journal-title":"Indian J Pediatr"},{"key":"1239_CR15","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.2147\/JIR.S477708","volume":"17","author":"H Cao","year":"2024","unstructured":"Cao H, Ma X. Rituximab in the treatment of non-infectious uveitis: a review. JIR. 2024;17:6765\u201380. https:\/\/doi.org\/10.2147\/JIR.S477708.","journal-title":"JIR"},{"issue":"6","key":"1239_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3341\/kjo.2023.0073","volume":"37","author":"S Lee","year":"2023","unstructured":"Lee S, Choo HG, Kwon OW, You YS. Effects of Subcutaneous methotrexate in patients with refractory uveitis and chorioretinitis. Korean J Ophthalmol. 2023;37(6):446\u201352. https:\/\/doi.org\/10.3341\/kjo.2023.0073.","journal-title":"Korean J Ophthalmol"},{"issue":"12","key":"1239_CR17","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1007\/s10792-023-02846-4","volume":"43","author":"C Evereklioglu","year":"2023","unstructured":"Evereklioglu C, Sonmez HK, Sevim DG, et al. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular beh\u00e7et syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation. Int Ophthalmol. 2023;43(12):4461\u201372. https:\/\/doi.org\/10.1007\/s10792-023-02846-4.","journal-title":"Int Ophthalmol"},{"key":"1239_CR18","doi-asserted-by":"publisher","unstructured":"Yiu MK, Ho M, Ho ACH, et al. Paediatric uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment. J Ophthal Inflamm Infect. 2024;14(1). https:\/\/doi.org\/10.1186\/s12348-024-00415-z.","DOI":"10.1186\/s12348-024-00415-z"},{"issue":"10","key":"1239_CR19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/09273948.2022.2161916","volume":"31","author":"A Marino","year":"2023","unstructured":"Marino A, Marelli L, Nucci P, Caporali R, Miserocchi E. Subcutaneous Tocilizumab in juvenile idiopathic arthritis associated uveitis. Ocul Immunol Inflamm. 2023;31(10):1997\u20132000. https:\/\/doi.org\/10.1080\/09273948.2022.2161916.","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"1239_CR20","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1080\/09273948.2022.2139274","volume":"31","author":"HK Sonmez","year":"2023","unstructured":"Sonmez HK, Evereklioglu C, Gulmez Sevim D. Prompt and sustained suppression of intraocular inflammation with adalimumab in pediatric patients with non-infectious uveitis resistant to traditional managements: a 6-month follow-up research. Ocul Immunol Inflamm. 2023;31(10):1992\u201396. https:\/\/doi.org\/10.1080\/09273948.2022.2139274.","journal-title":"Ocul Immunol Inflamm"},{"key":"1239_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","volume":"200","author":"N Vegas-Revenga","year":"2019","unstructured":"Vegas-Revenga N, Calvo-R\u00edo V, Mesquida M, Ad\u00e1n A, Hern\u00e1ndez MV, Beltr\u00e1n E, et al. Anti-IL6-receptor Tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85\u201394. https:\/\/doi.org\/10.1016\/j.ajo.2018.12.019.","journal-title":"Am J Ophthalmol"},{"key":"1239_CR22","doi-asserted-by":"publisher","unstructured":"Roberts JE, Nigrovic PA, Lo MS, Chang MH. Weekly Adalimumab, an effective alternative for refractory uveitis in children. J Clin Rheumatol. 2022;28(1):E301\u201304. https:\/\/doi.org\/10.1097\/RHU.0000000000001707.","DOI":"10.1097\/RHU.0000000000001707"},{"issue":"2","key":"1239_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/keaa595","volume":"60","author":"I Maccora","year":"2021","unstructured":"Maccora I, Fusco E, Marrani E, Ramanan A V, Simonini G. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatol (U Kingd). 2021;60(2):568\u201387. https:\/\/doi.org\/10.1093\/rheumatology\/keaa595.","journal-title":"Rheumatol (U Kingd)"},{"issue":"2","key":"1239_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/biomedicines11020629","volume":"11","author":"J Corredores","year":"2023","unstructured":"Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management. Biomedicines. 2023;11(2):629. https:\/\/doi.org\/10.3390\/biomedicines11020629.","journal-title":"Biomedicines"},{"key":"1239_CR25","doi-asserted-by":"publisher","unstructured":"Janetos TM, Kanwar K, Bashey S, Koreishi A, Goldstein DA. Predictors of therapy success in weekly adalimumab for refractory uveitis: a retrospective cohort study. Am J Ophthalmol. 270:1\u20137. https:\/\/doi.org\/10.1016\/j.ajo.2024.07.010. February 2024.","DOI":"10.1016\/j.ajo.2024.07.010"},{"issue":"9","key":"1239_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.4103\/ijo.IJO_966_20","volume":"68","author":"S Sadhu","year":"2020","unstructured":"Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India. Indian J Ophthalmol. 2020;68(9):1929\u201333. https:\/\/doi.org\/10.4103\/ijo.IJO_966_20.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"1239_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/17469899.2020.1739521","volume":"15","author":"J Rodriguez-Smith","year":"2020","unstructured":"Rodriguez-Smith J, Yeh S, Angeles-Han ST. Improving quick and accurate diagnosis of childhood JIA-uveitis from a pediatric rheumatology perspective. Expert Rev Ophthalmol. 2020;15(2):101\u201309. https:\/\/doi.org\/10.1080\/17469899.2020.1739521.","journal-title":"Expert Rev Ophthalmol"},{"key":"1239_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.12688\/f1000research.26689.1","volume":"9","author":"S Kellett","year":"2020","unstructured":"Kellett S, Rahi JS, Dick AD, Knowles R, Tadi\u0107 V, Solebo AL. UNICORNS: uveitis in childhood prospective national cohort study protocol. F1000Res. 2020;9:1196. https:\/\/doi.org\/10.12688\/f1000research.26689.1.","journal-title":"F1000Res"},{"key":"1239_CR29","doi-asserted-by":"publisher","unstructured":"Molimard J, Pajot C, Olle P, et al. Immunomodulatory treatment and surgical management of idiopathic uveitis and juvenile idiopathic arthritis-associated uveitis in children: a French survey practice. Pediatr Rheumatol. 2021;19(1). https:\/\/doi.org\/10.1186\/s12969-021-00626-x.","DOI":"10.1186\/s12969-021-00626-x"},{"issue":"6","key":"1239_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4274\/tjo.galenos.2024.70371","volume":"54","author":"\u00d6Y K","year":"2024","unstructured":"K \u00d6Y, O \u00d6, Y \u00d6E, P \u00c7\u00d6. The efficacy of Adalimumab treatment in Pediatric non-infectious uveitis: a retrospective cohort study. Turk J Ophthalmol. 2024;54(6):337\u201343. https:\/\/doi.org\/10.4274\/tjo.galenos.2024.70371.","journal-title":"Turk J Ophthalmol"},{"key":"1239_CR31","doi-asserted-by":"publisher","unstructured":"Utz VM, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol. 2019;17(1). https:\/\/doi.org\/10.1186\/s12969-019-0383-9.","DOI":"10.1186\/s12969-019-0383-9"},{"key":"1239_CR32","doi-asserted-by":"publisher","unstructured":"Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol. 2021;19(1). https:\/\/doi.org\/10.1186\/s12969-021-00630-1.","DOI":"10.1186\/s12969-021-00630-1"},{"issue":"20","key":"1239_CR33","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.3390\/diagnostics13203179","volume":"13","author":"I Maccora","year":"2023","unstructured":"Maccora I, De Libero C, Peri M, et al. Laser flare photometry to monitor childhood chronic uveitis: a preliminary report of a Monocentric Italian Experience. Diagnostics. 2023;13(20):3179. https:\/\/doi.org\/10.3390\/diagnostics13203179.","journal-title":"Diagnostics"},{"issue":"7","key":"1239_CR34","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/bjophthalmol-2019-314875","volume":"104","author":"CSY Cheung","year":"2020","unstructured":"Cheung CSY, Mireskandari K, Ali A, Silverman E, Tehrani N. Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis. Br J Ophthalmol. 2020;104(7):938\u201342. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314875.","journal-title":"Br J Ophthalmol"},{"key":"1239_CR35","doi-asserted-by":"publisher","unstructured":"Ramanan A V, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135\u201341. https:\/\/doi.org\/10.1016\/S2665-9913(20)30008-4.","DOI":"10.1016\/S2665-9913(20)30008-4"},{"issue":"9","key":"1239_CR36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/acr.21674","volume":"64","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A, Foeldvari I, Edelsten C, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis\u2013associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012;64(9):1365\u201372. https:\/\/doi.org\/10.1002\/acr.21674.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1239_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/ijr.12.83","volume":"8","author":"ST Angeles-Han","year":"2013","unstructured":"Angeles-Han ST, Yeh S, Vogler LB. Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis. Int J Clin Rheumtol. 2013;8(1):109\u201321. https:\/\/doi.org\/10.2217\/ijr.12.83.","journal-title":"Int J Clin Rheumtol"},{"issue":"5","key":"1239_CR38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","volume":"143","author":"JE Thorne","year":"2007","unstructured":"Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840\u20136.e2. https:\/\/doi.org\/10.1016\/j.ajo.2007.01.033.","journal-title":"Am J Ophthalmol"},{"key":"1239_CR39","doi-asserted-by":"crossref","unstructured":"Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis (JIA). Vol 143.; 2007.","DOI":"10.1016\/j.ajo.2006.11.025"},{"issue":"1","key":"1239_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00417-016-3497-5","volume":"255","author":"M Breitbach","year":"2017","unstructured":"Breitbach M, Tappeiner C, B\u00f6hm MRR, et al. Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2017;255(1):171\u201377. https:\/\/doi.org\/10.1007\/s00417-016-3497-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1239_CR41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00417-018-3928-6","volume":"256","author":"I Deitch","year":"2018","unstructured":"Deitch I, Amer R, Tomkins-Netzer O, et al. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):801\u201308. https:\/\/doi.org\/10.1007\/s00417-018-3928-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1239_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10792-016-0293-5","volume":"37","author":"A Mu\u00f1oz-Gallego","year":"2017","unstructured":"Mu\u00f1oz-Gallego A, Barral E, Enr\u00edquez E, Tejada P, Barcel\u00f3 A, de Inocencio J. Adalimumab for the treatment of refractory noninfectious paediatric uveitis. Int Ophthalmol. 2017;37(3):719\u201325. https:\/\/doi.org\/10.1007\/s10792-016-0293-5.","journal-title":"Int Ophthalmol"},{"issue":"7","key":"1239_CR43","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V, Allain-Launay E, Kon\u00e9-Paut I, Belot A, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheumatic Dis. 2018;77(7):1003\u201311. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212089.","journal-title":"Ann Rheumatic Dis"},{"issue":"17","key":"1239_CR44","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/nejmoa1614160","volume":"376","author":"V Ramanan A","year":"2017","unstructured":"Ramanan A V, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637\u201346. https:\/\/doi.org\/10.1056\/nejmoa1614160.","journal-title":"N Engl J Med"},{"issue":"11","key":"1239_CR45","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3899\/jrheum.151389","volume":"43","author":"C Birolo","year":"2016","unstructured":"Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol. 2016;43(11):2068\u201373. https:\/\/doi.org\/10.3899\/jrheum.151389.","journal-title":"J Rheumatol"},{"issue":"12","key":"1239_CR46","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183\u201388. https:\/\/doi.org\/10.3899\/jrheum.160231.","journal-title":"J Rheumatol"},{"issue":"6","key":"1239_CR47","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/09273948.2013.815785","volume":"21","author":"AT Vitale","year":"2013","unstructured":"Vitale AT, Graham E, De Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013;21(6):478\u201385. https:\/\/doi.org\/10.3109\/09273948.2013.815785.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"1239_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/09273948.2013.855798","volume":"23","author":"MP Paroli","year":"2015","unstructured":"Paroli MP, Abbouda A, Restivo L, Sapia A, Abicca I, Pezzi PP. Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm. 2015;23(1):74\u201381. https:\/\/doi.org\/10.3109\/09273948.2013.855798.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"1239_CR49","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.55563\/clinexprheumatol\/t7pn4v","volume":"42","author":"C Del-Prado-S\u00e1nchez","year":"2024","unstructured":"Del-Prado-S\u00e1nchez C, Llorca-Carde\u00f1osa A, Yeste-Mayoral B, Grixolli-Mazzon S, Barros-Centeno MF, D\u00edaz-Cascajosa J, et al. Optical coherence tomography for the screening of anterior chamber inflammation in paediatric patients diagnosed with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2024, Jul;42(7):1507\u201312. https:\/\/doi.org\/10.55563\/clinexprheumatol\/t7pn4v. Epub 2024 May 21. PMID: 38819950 .","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1239_CR50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09273948.2019.1674890","volume":"29","author":"FN Yal\u00e7\u0131nda\u011f","year":"2021","unstructured":"Yal\u00e7\u0131nda\u011f FN, G\u00fcng\u00f6r SG, De\u011firmenci MFK, Sar\u0131g\u00fcl Sezen\u00f6z A, \u00d6z\u00e7akar ZB, Bask\u0131n E, et al. The clinical characteristics of Pediatric non-infectious uveitis in Two tertiary referral Centers in Turkey. Ocul Immunol Inflamm. 2021;29(2):282\u201389. https:\/\/doi.org\/10.1080\/09273948.2019.1674890.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"1239_CR51","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1080\/09273948.2018.1529800","volume":"27","author":"WG Wieringa","year":"2019","unstructured":"Wieringa WG, Armbrust W, Legger GE, Los LI. Efficacy of high-dose methotrexate in Pediatric non-infectious uveitis. Ocul Immunol Inflamm. 2019;27(8):1305\u201313. https:\/\/doi.org\/10.1080\/09273948.2018.1529800.","journal-title":"Ocul Immunol Inflamm"},{"key":"1239_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/25158414211027707","volume":"13","author":"S Raveendra Murthy","year":"2021","unstructured":"Raveendra Murthy S, Ganesh S, M CK, Dubey N. Pediatric uveitis: a retrospective analysis at a tertiary eye care hospital in South India. Ophthalmol Eye Dis. 2021;13:13. https:\/\/doi.org\/10.1177\/25158414211027707.","journal-title":"Ophthalmol Eye Dis"},{"issue":"10","key":"1239_CR53","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ophtha.2006.05.016","volume":"113","author":"LI Kump","year":"2006","unstructured":"Kump LI, Casta\u00f1eda RAC, Androudi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis\u2013associated uveitis. Ophthalmology. 2006;113(10):1874\u201377. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.016.","journal-title":"Ophthalmology"},{"issue":"2","key":"1239_CR54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0161-6420(97)30329-7","volume":"104","author":"MR Dana","year":"1997","unstructured":"Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis- associated uveitis. Ophthalmology. 1997;104(2):236\u201344. https:\/\/doi.org\/10.1016\/S0161-6420(97)30329-7.","journal-title":"Ophthalmology"},{"issue":"1","key":"1239_CR55","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","volume":"120","author":"AC Gregory","year":"2013","unstructured":"Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2013;120(1):186\u201392. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.052.","journal-title":"Ophthalmology"},{"key":"1239_CR56","doi-asserted-by":"crossref","unstructured":"Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Vol 86.; 2002. https:\/\/www.bjophthalmol.com.","DOI":"10.1136\/bjo.86.1.51"},{"key":"1239_CR57","doi-asserted-by":"publisher","unstructured":"Sabri K, Saurenmann RK, Silverman ED, Levin A V. Course, complications, and outcome of juvenile arthritis\u2013related uveitis. J Am Assoc Pediatr Ophthalmol Strabismus. 2008;12(6):539\u201345. https:\/\/doi.org\/10.1016\/j.jaapos.2008.03.007.","DOI":"10.1016\/j.jaapos.2008.03.007"},{"issue":"10","key":"1239_CR58","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1080\/09273948.2023.2166849","volume":"31","author":"Clli van Meerwijk","year":"2023","unstructured":"van Meerwijk Clli, Wieringa WG, de Boer JH, Jansonius NM, Los LI. Factors associated with glaucoma surgery in Pediatric non-infectious uveitis. Ocul Immunol Inflamm. 2023;31(10):2018\u201323. https:\/\/doi.org\/10.1080\/09273948.2023.2166849.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"1239_CR59","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/art.22381","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Levin A V, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheumatism. 2007;56(2):647\u201357. https:\/\/doi.org\/10.1002\/art.22381.","journal-title":"Arthritis Rheumatism"},{"key":"1239_CR60","doi-asserted-by":"publisher","unstructured":"Morelle G, Gueudry J, Uettwiller F, et al. Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open. 2019;5(2):e000933. https:\/\/doi.org\/10.1136\/rmdopen-2019-000933.","DOI":"10.1136\/rmdopen-2019-000933"},{"issue":"7\u20138","key":"1239_CR61","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1080\/09273948.2020.1758731","volume":"29","author":"ST Angeles-Han","year":"2021","unstructured":"Angeles-Han ST, Miraldi Utz V, Thornton S, et al. S100 proteins, Cytokines, and Chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm. 2021;29(7\u20138):1616\u201320. https:\/\/doi.org\/10.1080\/09273948.2020.1758731.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1239_CR62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/09273948.2024.2428846","volume":"33","author":"I Maccora","year":"2024","unstructured":"Maccora I, Altaye M, Greis KD, et al. Candidate Tear-based uveitis biomarkers in children with JIA based on arthritis activity and topical corticosteroid use. Ocul Immunol Inflamm. Published online 2024. doi: 33(4):603\u201312. https:\/\/doi.org\/10.1080\/09273948.2024.2428846.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"1239_CR63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3109\/09273948.2013.815786","volume":"21","author":"S Jawad","year":"2013","unstructured":"Jawad S, Liu B, Agron E, Nussenblatt RB, Sen HN. Elevated serum levels of interleukin-17A in uveitis patients. Ocul Immunol Inflamm. 2013;21(6):434\u201339. https:\/\/doi.org\/10.3109\/09273948.2013.815786.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"1239_CR64","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1167\/iovs.12-10865","volume":"54","author":"V Kalinina Ayuso","year":"2013","unstructured":"Kalinina Ayuso V, de Boer JH, Byers HL, et al. Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci. 2013;54(5):3709\u201320. https:\/\/doi.org\/10.1167\/iovs.12-10865.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1239_CR65","first-page":"2446","volume":"29","author":"F Zulian","year":"2002","unstructured":"Zulian F, Martini G, Falcini F, Gerloni V, Zannin ME, Pinello L, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol. 2002;29(11):2446\u201353.","journal-title":"J Rheumatol"},{"issue":"2","key":"1239_CR66","first-page":"116","volume":"39","author":"R Campanilho-Marques","year":"2014","unstructured":"Campanilho-Marques R, Bogas M, Ramos F, Santos MJ, Fonseca JE. Prognostic value of antinuclear antibodies in juvenile idiopathic arthritis and anterior uveitis. Results from a systematic literature review. Acta Reumatol Port. 2014;39(2):116\u201322.","journal-title":"Acta Reumatol Port"},{"issue":"11","key":"1239_CR67","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/acr.22627","volume":"67","author":"ST Angeles-Han","year":"2015","unstructured":"Angeles-Han ST, Yeh S, McCracken C, et al. Using the effects of youngsters\u2019 eyesight on quality of life questionnaire to measure visual outcomes in children with uveitis. Arthritis Care Res (Hoboken). 2015;67(11):1513\u201320. https:\/\/doi.org\/10.1002\/acr.22627.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1239_CR68","doi-asserted-by":"publisher","unstructured":"Sen ES, Morgan MJ, MacLeod R, et al. Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol. 2017;15(1). https:\/\/doi.org\/10.1186\/s12969-017-0189-6.","DOI":"10.1186\/s12969-017-0189-6"},{"issue":"9","key":"1239_CR69","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/acr.20524","volume":"63","author":"ST Angeles-Han","year":"2011","unstructured":"Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8\u201318 years for use in juvenile idiopathic arthritis\u2013associated uveitis. Arthritis Care Res (Hoboken). 2011;63(9):1254\u201361. https:\/\/doi.org\/10.1002\/acr.20524.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"1239_CR70","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1239_CR71","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/ceo.14175","volume":"50","author":"DA Jabs","year":"2022","unstructured":"Jabs DA, McCluskey P, Palestine AG, et al. The standardisation of uveitis nomenclature (SUN) project. Clin Exper Ophthalmol. 2022;50(9):991\u20131000. https:\/\/doi.org\/10.1111\/ceo.14175.","journal-title":"Clin Exper Ophthalmol"},{"issue":"8","key":"1239_CR72","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s10792-018-1005-0","volume":"39","author":"E Baghdasaryan","year":"2019","unstructured":"Baghdasaryan E, Tepelus TC, Marion KM, et al. Analysis of ocular inflammation in anterior chamber\u2014involving uveitis using swept-source anterior segment OCT. Int Ophthalmol. 2019;39(8):1793\u2013801. https:\/\/doi.org\/10.1007\/s10792-018-1005-0.","journal-title":"Int Ophthalmol"},{"issue":"11","key":"1239_CR73","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ophtha.2017.05.013","volume":"124","author":"A Invernizzi","year":"2017","unstructured":"Invernizzi A, Marchi S, Aldigeri R, et al. Objective quantification of anterior chamber inflammation: measuring cells and flare by anterior segment optical coherence tomography. Ophthalmology. 2017;124(11):1670\u201377. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.013.","journal-title":"Ophthalmology"},{"issue":"19","key":"1239_CR74","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.3390\/jcm10194513","volume":"10","author":"C Tappeiner","year":"2021","unstructured":"Tappeiner C, Bae HS, Rothaus K, Walscheid K, Heiligenhaus A. Occurrence and risk factors for macular edema in patients with juvenile idiopathic arthritis-associated uveitis. JCM. 2021;10(19):4513. https:\/\/doi.org\/10.3390\/jcm10194513.","journal-title":"JCM"},{"issue":"13","key":"1239_CR75","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1167\/iovs.15-17066","volume":"56","author":"K Walscheid","year":"2015","unstructured":"Walscheid K, Heiligenhaus A, Holzinger D, et al. Elevated S100A8\/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis- associated uveitis: results from a pilot study. Invest Ophthalmol Vis Sci. 2015;56(13):7653\u201360. https:\/\/doi.org\/10.1167\/iovs.15-17066.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"1239_CR76","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jaapos.2009.12.160","volume":"14","author":"ST Angeles-Han","year":"2010","unstructured":"Angeles-Han ST, Griffin KW, Lehman TJA, et al. The importance of visual function in the quality of life of children with uveitis. J Am Assoc Pediatr Ophthalmol Strabismus. 2010;14(2):163\u201368. https:\/\/doi.org\/10.1016\/j.jaapos.2009.12.160.","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"5","key":"1239_CR77","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheumatism. 2009;61(5):658\u201366. https:\/\/doi.org\/10.1002\/art.24516.","journal-title":"Arthritis Rheumatism"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01239-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:08:56Z","timestamp":1789434536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01239-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01239-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable due to this is a systematic literature review.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"62"}}